Craig-Hallum Sticks to Its Buy Rating for Ironwood Pharma (IRWD)
Craig-Hallum analyst Chase Knickerbocker maintained a Buy rating on Ironwood Pharma yesterday. The company’s shares closed yesterday at $3.17.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Knickerbocker covers the Healthcare sector, focusing on stocks such as Indivior, Eton Pharmaceuticals, and Ironwood Pharma. According to TipRanks, Knickerbocker has an average return of 31.2% and a 55.70% success rate on recommended stocks.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Ironwood Pharma with a $7.50 average price target.
Based on Ironwood Pharma’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $47.71 million and a GAAP net loss of $2.28 million. In comparison, last year the company earned a revenue of $90.55 million and had a net profit of $2.26 million
Based on the recent corporate insider activity of 36 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of IRWD in relation to earlier this year. Last month, Thomas Mccourt, the CEO of IRWD sold 103,526.00 shares for a total of $378,905.16.
Read More on IRWD:
